Iberdomide (CC-220)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Iberdomide (CC-220), covering 2024-07-26 to 2026-01-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]